VERTEX PHARMACEUTICALS INC / MA (VRTX) Debt Components
- 2016-12-31: Senior Notes, CurrentUSD $0.00; Secured DebtUSD (m); Long-term Line of CreditUSD (m); Long-term DebtUSD (m).
- 2016-09-30: Senior Notes, CurrentUSD $297.75M; Secured DebtUSD (m); Long-term Line of CreditUSD (m); Long-term DebtUSD (m).
- 2016-06-30: Senior Notes, CurrentUSD $221.58M; Secured DebtUSD (m); Long-term Line of CreditUSD (m); Long-term DebtUSD (m).
- 2016-03-31: Senior Notes, CurrentUSD $146.25M; Secured DebtUSD (m); Long-term Line of CreditUSD (m); Long-term DebtUSD (m).
VERTEX PHARMACEUTICALS INC / MA Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Senior Notes, Current USD | Secured Debt USD | Long-term Line of Credit USD | Long-term Debt USD | Line of Credit Facility, Current Borrowing Capacity USD | Debt Instrument, Face Amount USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Interest Rate, Effective Percentage pure | Debt Instrument, Convertible, Conversion Ratio (Deprecated 2013-01-31) pure | Debt Instrument, Increase, Additional Borrowings (Deprecated 2013-01-31) USD | Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) USD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $297.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $221.58M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $146.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $71.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | $21.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $42.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $28.53M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $14.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $32.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $33.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $33.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | 9.00% | 2.00% | (m) | (m) | $31.90M |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | 7.00% | 3.00% | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $31.90M |
| 2013-06-30 | (m) | (m) | (m) | (m) | $31.90M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | 7.00% | 4.00% | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 4.00% | (m) | (m) | (m) |
| 2011-09-30 | (m) | $92.36M | (m) | $105.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $89.69M | (m) | $105.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | $87.11M | (m) | $105.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $124.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | $121.33M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $111.31M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $155.00M | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $155.00M | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | $155.00M | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 4322.00% | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |